Drug Trial Radar · NCT02794571
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
518
Actual
Start
May 23, 2016
Primary completion
Nov 13, 2024
Study completion Nov 13, 2024
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
Conditions
- Advanced/Metastatic Tumors
Interventions
AtezolizumabDrug
Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
TiragolumabDrug
Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
CarboplatinDrug
Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
CisplatinDrug
Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
PemetrexedDrug
Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
PaclitaxelDrug
Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
EtoposideDrug
Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
CapecitabineDrug
Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
BevacizumabDrug
Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
PembrolizumabDrug
Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: From Baseline to the end of Cycle 1 (up to 21 days)
- Percentage of Participants with Adverse Events (AEs) Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0Time frame: From Baseline up to 90 days after last dose of study treatment or until initiation of another systemic anti-cancer therapy (up to approximately 8 years)
- Number of Cycles with TiragolumabTime frame: From Baseline to last dose (up to approximately 8 years)
- Phase Ia and Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to TiragolumabTime frame: Day 1 up to 8 years
- Phase Ib: Percentage of Participants with ADAs to AtezolizumabTime frame: Day 1 up to 8 years
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
University of California Los Angeles
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Memorial Sloan-Kettering Cancer Center
New York, New York
Tennessee Oncology - Nashville
Nashville, Tennessee
Kinghorn Cancer Centre; St Vincents Hospital
Darlinghurst, New South Wales, Australia
Peter MacCallum Cancer Center
North Melbourne, Victoria, Australia
Princess Margaret Hospital
Toronto, Ontario, Canada
Institut Bergonie CLCC Bordeaux
Bordeaux, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, France
Institut Curie
Paris, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Institut Gustave Roussy
Villejuif, France
National Cancer Center Hospital
Tokyo, Japan
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Tokyo, Japan
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital del Mar
Barcelona, Spain
Hospital Universitario HM Sanchinarro-CIOCC; Oncología Médica
Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
ICO L'Hospitalet; Servicio de oncologia medica
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Sant Andreu de la Barca, Barcelona, Spain
Clinica Universitaria de Navarra; Servicio de oncología
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.